ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial

Cheng, Ying*; Wang, Qiming; Li, Kai; Shi, Jianhua; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, Xiaoling广州医学院; 上海交通大学; 哈尔滨医科大学; 郑州大学; 中国医学科学院; 1; 5; y
Cancer Medicine2022-2DOI: 10.1002/cam4.4507
9被引3阅读
引用收藏
分享

摘要

Liver metastasis is common in advanced small cell lung cancer (SCLC). There is no evidence-proven treatment beyond the second line in patients with SCLC and liver metastasis. This study aimed to investigate survival in patients with SCLC and liver metastasis treated with anlotinib compared with placebo. This study was a post hoc analysis of the phase II ALTER 1202 trial, including patients who had liver metastasis at baseline. The participants were randomized 2:1 to receive either 12 mg/day anlotinib (anlotinib group) or placebo (placebo group). Tumor response, progression-free survival (PFS), and overall survival (OS) were compared. In the original trial, there were 39 participants with liver metastasis at baseline, including 27 and 12 in the anlotinib and placebo groups, respectively. The objective response rate was 3.7% and 0% in the anlotinib and placebo groups, respectively (p = 0.9999). An elevated disease control rate was found in the anlotinib group (44.4%) compared with the placebo group (8.3%, p = 0.0173). The median PFS was 1.51 vs. 0.71 months in favor of anlotinib (hazard ratio [HR] = 0.365, 95% confidence interval [CI]: 0.17-0.78; p = 0.0064), with no marked difference in median OS (3.29 vs. 1.91 months; HR = 0.51, 95% CI: 0.22-1.16; p = 0.0996). The most common AEs in the anlotinib group were hypertension (40.7%), fatigue (29.6%), loss of appetite (22.2%), and weight loss (22.2%). There were no grade 5 AE. In conclusion, anlotinib increased PFS compared with placebo in patients with SCLC and liver metastasis.

学科与关键词

关键词
adverse eventsanlotinibliver metastasissmall cell lung cancersurvival
相关
加载中…
  • Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
    Shi, Jianhua; Cheng, Ying*; Wang, Qiming; Li, Kai; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, XiaolingFrontiers of Medicine, 2022, 16(5): 766-772.被引 5
  • Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
    Cheng, Y.; Yang, R.; Chen, J.; Zhang, W.; Xie, C.; Hu, Q.; Zhou, N.; Huang, C.; Wei, S.; Sun, H.; Li, X.; Yu, Y.; Lai, J.; Yang, H.; Fang, H.; Chen, H.; Zhang, P.; Gu, K.; Wang, Q.; Shi, J.; Yi, T.; Xu, X.; Ye, X.; Wang, D.; Xie, C.; Liu, C.; Zheng, Y.; Lin, D.; Zhuang, W.; Lu, P.; Yu, G.; Li, J.; Gu, Y.; Li, B.; Wu, R.; Jiang, O.; Wang, Z.; Wu, G.; Lin, H.; Zhong, D.; Xu, Y.; Shu, Y.; Wu, D.; Chen, X.; Wang, J.; Wang, M.
  • The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen*; Jin, Feng; Cheng, Boran; Zhang, Yue; Zhou, Qing; Wang, ShubinJournal of Cancer Research and Clinical Oncology, 2022, 148(7): 1721-1735.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Medicine
发表日期
2022-02
卷期
第 11 卷, 第 4 期
页码
1081-1087
DOI
10.1002/cam4.4507
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Jilin Province Development and Reform Commission [2021C043-1, 2021C042-7]; Jilin Provincial Health and Family Planning Commission [2019J077]; Science and Technology Agency of Jilin Provincial Project [20200201518JC]; Chia-Tai Tianqing Pharmaceutical Group Co., Ltd.

作者

  • C

    Cheng, Ying (通讯) (第一作者)

  • W

    Wang, Qiming

    zhengzhou univ

查看全部 11 位作者收起作者
  • L

    Li, Kai

    tianjin med univ

  • S

    Shi, Jianhua

  • W

    Wu, Lin

    hunan canc hosp

  • H

    Han, Baohui

    shanghai jiao tong univ

  • C

    Chen, Gongyan

    harbin med univ

  • H

    He, Jianxing

    1 · guangzhou med univ

  • W

    Wang, Jie

    chinese acad med sci

  • Q

    Qin, Haifeng

    5 · chinese peoples liberat army gen hosp

  • L

    Li, Xiaoling

    liaoning canc hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417